MYO18A and diabetes mellitus: Novel targets include MYO18A, SEC16A, CCNB1, MAD2L1, hsa-mir-4315, hsa-mir-6134, hsa-mir-9500, KIFC3, FBL (fibrillarin), TUBA1A and GFI1B might have crucial biologic functions in the pathogenesis of patients with diabetes mellitus and obesity.